NUSINERSEN
Information current as at: 1 September 2024
Submission Details
- Brand name:
-
- Spinraza®
- Pharmaceutical company:
- Biogen Australia Pty Ltd
- Condition/indication:
(therapeutic use) -
- Spinal muscular atrophy (SMA)
- PBAC Submission type:
- Change to listing (Major)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – July 2020
- Related medicines:
Progress Details
-
Submission received for: - July 2020 PBAC meeting
-
Opportunity for consumer comment: - Open 29/04/2020 and close 10/06/2020 (see PBS Website)
-
PBAC meeting: - Held on 08/07/2020
-
Lodgement of required documentation: - 11/09/2020
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 26/10/2020
-
Status:
- Finalised
-
Government processes: - Commenced on 28/11/2020
-
Medicine listed on the PBS: - 01/12/2020 (see PBS schedule)
Case ID: a197
Page last updated: 02 May 2024